Maternal Conditions Affecting the Newborn
Read the mother's chart to predict the newborn's problems
Infant of a diabetic mother
One mechanism, many problems. Glucose crosses the placenta but insulin does not. Maternal hyperglycemia therefore causes fetal hyperglycemia, fetal β-cell hyperplasia, and fetal hyperinsulinism. Insulin acts as a growth factor, producing macrosomia with excess fat and organomegaly while the head is relatively spared; the broad shoulders predispose to shoulder dystocia, brachial plexus injury, clavicle fracture, and asphyxia. Hyperinsulinism also raises fetal oxygen consumption, and the resulting hypoxemia drives erythropoietin and red cell production.
| Problem | Cause | Recognition and management |
|---|---|---|
| Hypoglycemia | Hyperinsulinism persists after cord clamping | First 1–2 hours; jitteriness, poor feeding, apnea, seizures, or no symptoms; feed within the first hour, check glucose about 30 minutes after the first feed and then before feeds for at least 12 hours, dextrose gel for mild lows, IV D10 (2 mL/kg bolus, then infusion) if symptomatic or persistent |
| Hypocalcemia, hypomagnesemia | Functional hypoparathyroidism; maternal glycosuric Mg wasting, and low Mg blunts PTH | 24–72 hours; jitteriness, tetany, seizures; replace Mg if calcium will not correct |
| Polycythemia | Fetal hypoxemia → erythropoietin | Venous Hct >65%; plethora, lethargy, poor feeding, respiratory distress, hypoglycemia, renal vein thrombosis, NEC; partial exchange with normal saline if symptomatic |
| Hyperbilirubinemia | Increased RBC breakdown, immature conjugation | Bilirubin monitoring and phototherapy per thresholds |
| Respiratory distress syndrome | Insulin antagonizes cortisol-driven surfactant synthesis | Occurs at gestational ages when other lungs are mature |
| Septal hypertrophy | Insulin-driven myocardial growth | Murmur ± outflow obstruction or heart failure on echocardiogram; supportive care ± propranolol; regresses over weeks to months |
In transient hypertrophic cardiomyopathy, inotropes such as digoxin or dobutamine worsen dynamic outflow obstruction and should be avoided.
Lung maturity testing. In diabetic pregnancies the lecithin/sphingomyelin ratio can look mature while surfactant is still deficient, so the presence of phosphatidylglycerol is the more reliable marker. Tight maternal glucose control lowers the risk of RDS and of macrosomia.
Malformations. Poor glycemic control around conception (reflected by an elevated HbA1c) raises the risk of congenital heart disease (transposition, VSD, truncus arteriosus), neural tube defects, renal anomalies, and caudal regression (sacral agenesis), the most specific diabetic embryopathy. Small left colon syndrome presents as failure to pass meconium and abdominal distension; a contrast enema shows a narrow descending colon up to the splenic flexure and is often therapeutic. Gestational diabetes starts after organogenesis, so it causes macrosomia and metabolic problems but not malformations.
Neonatal opioid withdrawal
Presentation. Infants exposed in utero to heroin, prescription opioids, methadone, or buprenorphine usually develop withdrawal at 1–3 days, earlier with short-acting drugs; methadone withdrawal tends to be longer and more severe than buprenorphine withdrawal. Signs are neurologic (irritability, high-pitched cry, tremor, hypertonia, poor sleep, rarely seizures), autonomic (sweating, sneezing, yawning, nasal stuffiness, fever), and gastrointestinal (poor feeding, vomiting, diarrhea, poor weight gain).
- Keep mother and baby togetherRooming-in, skin-to-skin contact, swaddling, low stimulation, on-demand feeding.
- Assess functionCan the infant eat (≥1 oz per feed or breastfeed well), sleep ≥1 hour, and be consoled within 10 minutes?
- Optimize nonpharmacologic careAny "no" first prompts more parental presence and support.
- Medicate if still failingOral morphine or methadone; clonidine or phenobarbital as adjuncts (phenobarbital especially with polysubstance exposure).
Breastfeeding. Encouraged when the mother is stable on methadone or buprenorphine, because little drug reaches the milk and nursing lessens withdrawal; it is avoided with ongoing illicit drug use.
Naloxone is contraindicated in the newborn of an opioid-dependent mother because it can precipitate acute withdrawal and seizures.
Fetal alcohol syndrome and other exposures
Fetal alcohol syndrome. The most severe form of fetal alcohol spectrum disorder and the leading preventable cause of intellectual disability. The facial triad is a smooth philtrum, thin upper vermilion, and short palpebral fissures, accompanied by prenatal and postnatal growth deficiency, microcephaly, and neurodevelopmental problems such as intellectual disability and ADHD-like behavior; septal heart defects can occur. There is no safe amount or trimester of alcohol use in pregnancy.
Other maternal factors. Smoking causes fetal growth restriction and raises SIDS risk; cocaine is linked to placental abruption, growth restriction, and preterm birth. Uncontrolled maternal phenylketonuria exposes the fetus to high phenylalanine, causing microcephaly, intellectual disability, and heart defects, which is why a low-phenylalanine diet is resumed before conception.
Transplacental maternal antibodies
The IgG rule. Only IgG crosses the placenta. Diseases caused by maternal IgG are therefore transient and fade as the antibody is cleared over the first months, unless the antibody caused fixed tissue damage, as in congenital heart block.
| Maternal antibody | Neonatal disease | Course and management |
|---|---|---|
| Anti-Ro/SSA (± anti-La) | Neonatal lupus: complete heart block, annular photosensitive periorbital rash, cytopenias, transaminitis | Heart block permanent (pacemaker if needed); the rest clears by ~6 months |
| Thyroid-stimulating immunoglobulin | Neonatal thyrotoxicosis: tachycardia, irritability, poor weight gain, goiter, heart failure | Methimazole + propranolol; resolves in ~1–3 months |
| Anti-AChR (or anti-MuSK) | Transient neonatal myasthenia: hypotonia, weak suck and cry, poor feeding, ptosis, facial weakness, respiratory failure | Supportive care ± neostigmine or pyridostigmine; resolves within ~2 months |
| Antiplatelet IgG | Maternal ITP or NAIT (below) | Serial platelet counts; IVIG or antigen-negative platelets |
Neonatal lupus. The mother is often asymptomatic or has Sjögren syndrome or SLE. Fetal bradycardia from complete heart block develops around 16–24 weeks, so anti-Ro–positive pregnancies are monitored with fetal echocardiography. Neonatal thyrotoxicosis can occur even after the mother's thyroid was removed or ablated, because the antibodies persist; onset may be delayed several days while maternal antithyroid drug wears off. Transient neonatal myasthenia affects about 10–20% of infants of mothers with myasthenia, appears within the first 1–3 days, and does not track maternal disease severity.
| Feature | Maternal ITP | NAIT |
|---|---|---|
| Antibody | Autoantibody against all platelets | Alloantibody against a paternal antigen the mother lacks (usually HPA-1a) |
| Mother's platelets | Low, or known ITP | Normal; can affect a first pregnancy |
| Neonatal severity | Usually mild; nadir at 2–5 days; hemorrhage rare | Often severe; intracranial hemorrhage, frequently in utero |
| Management | Serial counts; IVIG if severe or bleeding | Head ultrasound; HPA-1a–negative platelets (random-donor if unavailable) + IVIG; maternal IVIG ± steroids in later pregnancies |